MT Combined With XKSA for Depressive Symptoms During COVID-19
Depression, Anxiety
About this trial
This is an interventional treatment trial for Depression, Anxiety focused on measuring Morita therapy, acupressure, quarantine, COVID-19, depression, anxiety
Eligibility Criteria
Inclusion Criteria: age 18 to 65 years; a PHQ-9 score of > 4 (indicative of mild depression); shinkeishitsu-type neurosis including introspective, sensitive, serious, careful, timid, cautious, perfectionistic, or rigid character, assessed by the Diagnostic Interview of Morita shinkeishitsu (DIM); absence of any problems involving injuries, inflammation, or space-occupying lesions at the locations of the acupoints; ability to understand the trial process; no engagement in other forms of activities to improve mood and sleep (e.g., Tai Chi, yoga, and mindfulness meditation) in the last three months before and during the trial. Exclusion Criteria: severe physical and psychiatric diseases; inability to complete the trial or use necessary psychiatric medicine; cognitive dysfunction caused by neurodegenerative and neurodevelopmental disorders, such as dementia, mental retardation, and autism spectrum disorder; self-injurious or suicidal risk; positive COVID-19 nucleic acid test results.
Sites / Locations
- Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Morita therapy (MT) combined with Xingnao Kaiqiao self-administered acupressure (XKSA)
Morita therapy (MT)
MT combined with XKSA for 2 weeks.
MT alone for 2 weeks